Less Ads, More Data, More Tools Register for FREE

Thursday broker round-up

Thu, 27th Oct 2016 12:29
(ShareCast News) - Debenhams: JP Morgan keeps at underweight with a target price of 54p.AA: Berenberg stays at buy, 315p target.National Express: RBC reiterates outperform with a 405p target.LLoyds: UBS reiterates buy with a 67p target.GlaxoSmithKline: Credit Suisse reiterates neutral with a 1800p target.Kingfisher: JP Morgan keeps at underweight with a target price of 280p.AG Barr: Berenberg keeps at sell with a target price of 470p.WH Smith: JP Morgan stays at overweight with a 1850p target.Antofagasta: UBS upgrades to neutral with a 500p target.Marks & Spencer: JP Morgan stays at underweight with a 285p target.Shanks Group: Credit Suisse reiterates outperform with a 115p target. Kingfisher Lloyds Wh Smith Marks & Spencer Glaxosmithkline Barr (A.G.) Antofagasta

Shares in this article

Related News

GSK, Hansoh's targeted cancer drug hits main survival goal in China trial
18 hours ago

GSK, Hansoh's targeted cancer drug hits main survival goal in China trial

* GSK partner Hansoh reports first late-stage data ​for experimental ⁠lung cancer drug

GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial
20 hours ago

GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial

(Alliance News) - GSK PLC on Friday announced that risvutatug rezetecan has delivered "meaningful" survival data in a "pivotal" trial for advanced or ...

GSK hails 'milestone' drug trial results in China
21 hours ago

GSK hails 'milestone' drug trial results in China

(Sharecast News) - A targeted lung cancer treatment developed by GSK has shown promising results in the latest trials in China, the pharma blue chip c...